Patents by Inventor Bart Rutten

Bart Rutten has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140181312
    Abstract: Systems and methods for peer-to-peer communication between user equipment using IP multimedia subsystem (IMS) functionality are provided. Each peer user equipment includes an IMS server and the peer-to-peer communication is established independent of network-based IMS servers. A third user equipment that does not include an IMS server can join the peer-to-peer communication using network-based IMS servers.
    Type: Application
    Filed: September 20, 2011
    Publication date: June 26, 2014
    Applicant: Nexios IT
    Inventors: Bart Rutten, Subramanian Sahasranaman
  • Patent number: 7534871
    Abstract: Novel carbohydrate-based compounds with an attached ring system that have antimicrobial or cytostatic activity. The compounds are administered to humans and animals for the treatment or amelioration of bacterial, fungal, viral or protozoal infections or tumors.
    Type: Grant
    Filed: June 4, 2004
    Date of Patent: May 19, 2009
    Assignee: Kemin Pharma B.V.B.A.
    Inventors: Benedikt Sas, Johan van der Eycken, Johan Van hemel, Petra Blom, Jan Vandenkerckhove, Bart Ruttens
  • Patent number: 7138531
    Abstract: Novel carbohydrate-based compounds with an attached ring system that have antimicrobial or cytostatic activity. The compounds are administered to humans and animals for the treatment or amelioration of bacterial, fungal, viral or protozoal infections or tumors.
    Type: Grant
    Filed: October 15, 2001
    Date of Patent: November 21, 2006
    Assignee: Kemin Pharma B.V.B.A.
    Inventors: Benedikt Sas, Johan van der Eycken, Johan Van hemel, Petra Blom, Jan Vandenkerckhove, Bart Ruttens
  • Patent number: 7125854
    Abstract: The use of bicyclic carbohydrates for the treatment of parasite infections is described. Different bicyclic carbohydrates have been tested in vitro against a number of protozoa. These compounds also have been screened against viruses, tumors, bacteria and fungi. Compound A1, a thiophenyl-containing bicyclic carbohydrate possessed significant activity against Trypanosoma brucei rhodiense, a parasite that causes the lethal sleeping sickness. Compound A2 and Compound A3, bicyclic carbohydrates with halogen containing aryl groups, possessed significant activity against Leishmania donovani, a parasite that causes leishmaniasis. Bicyclic carbohydrates in general, and Compound A1, Compound A2 and Compound A3 more specifically, could be possible treatments for the sleeping sickness and leishmaniasis in the future.
    Type: Grant
    Filed: January 7, 2004
    Date of Patent: October 24, 2006
    Assignee: Kemin Pharma B.V.B.A.
    Inventors: Benedikt Sas, Johan Van hemel, Jan Vandenkerckhove, Eric Peys, Johan Van der Eycken, Bart Ruttens
  • Patent number: 7125853
    Abstract: We describe the use of bicyclic carbohydrates for the treatment of hepatitis C virus infections. Different bicyclic carbohydrates were tested in vitro against DNA-viruses, retro-viruses and Flaviviridae sp., an important family of human and animal RNA pathogens. Significant activity was observed against the bovine viral diarrhea virus (BVDV). As pestiviruses, such as BVDV, share many similarities with hepatitis C virus (HCV), the bicyclic carbohydrates in general and the preferred bicyclic carbohydrates more specifically are expected to be a treatment for hepatitis C viral infections.
    Type: Grant
    Filed: December 22, 2003
    Date of Patent: October 24, 2006
    Assignee: Kemin Pharma B.V.B.A.
    Inventors: Benedikt Sas, Johan Van hemel, Jan Vandenkerckhove, Eric Peys, Johan Van der Eycken, Bart Ruttens, Jan Balzarini, Eric De Clercq, Johan Neyts
  • Patent number: 7101908
    Abstract: Bicyclic carbohydrates for the treatment of infections caused by herpseviridae, and in particular cytomegalovirus. The invention consists of the novel bicyclic carbohydrates the generic structure of which is: wherein R1 is either -Bn or -Ph; R2 and R3 are either -alkyl, -aryl, -allyl, or —H; R4 and R5 form a ring and are either —CH(Ph)- or —CH(aryl)- and X is either O, N or S.
    Type: Grant
    Filed: October 22, 2003
    Date of Patent: September 5, 2006
    Assignee: Kemin Pharma Europe B.V.B.A.
    Inventors: Benedikt Sas, Johan Van Hemel, Jan Vandenkerckhove, Eric Peys, Johan van der Eycken, Bart Ruttens, Petra Blom
  • Publication number: 20050267048
    Abstract: Bicyclic carbohydrates for the treatment of infections caused by herpseviridae, and in particular cytomegalovirus. The invention consists of the novel bicyclic carbohydrates the generic structure of which is: wherein R1 is either -Bn or -Ph; R2 and R3 are either -alkyl, -aryl, -allyl, or —H; R4 and R5 form a ring and are either —CH(Ph)- or —CH(aryl)- and X is either O, N or S.
    Type: Application
    Filed: October 22, 2003
    Publication date: December 1, 2005
    Inventors: Benedikt Sas, Johan hemel, Jan Vandenkerckhove, Eric Peys, Johan Eycken, Bart Ruttens, Petra Blom
  • Publication number: 20050090452
    Abstract: Bicyclic carbohydrates for the treatment of infections caused by herpseviridae, and in particular cytomegalovirus. The invention consists of the novel bicyclic carbohydrates the generic structure of which is: wherein R1 is either -Bn or -Ph; R2 and R3 are either -alkyl, -aryl, -allyl, or —H; R4 and R5 form a ring and are either —CH(Ph)- or —CH(aryl)- and X is either O, N or S.
    Type: Application
    Filed: October 22, 2003
    Publication date: April 28, 2005
    Inventors: Benedikt Sas, Johan hemel, Jan Vandenkerckhove, Eric Peys, Johan Eycken, Bart Ruttens, Petra Blom
  • Publication number: 20040224904
    Abstract: Novel carbohydrate-based compounds with an attached ring system that have antimicrobial or cytostatic activity. The compounds are administered to humans and animals for the treatment or amelioration of bacterial, fungal, viral or protozoal infections or tumors.
    Type: Application
    Filed: June 4, 2004
    Publication date: November 11, 2004
    Inventors: Benedikt Sas, Johan Van der Eycken, Johan Van hemel, Petra Blom, Jan Vandenkerckhove, Bart Ruttens
  • Publication number: 20040209823
    Abstract: We describe the use of bicyclic carbohydrates for the treatment of hepatitis C virus infections. Different bicyclic carbohydrates were tested in vitro against DNA-viruses, retro-viruses and Flaviviridae sp., an important family of human and animal RNA pathogens. Significant activity was observed against the bovine viral diarrhea virus (BVDV). As pestiviruses, such as BVDV, share many similarities with hepatitis C virus (HCV), the bicyclic carbohydrates in general and the preferred bicyclic carbohydrates more specifically are expected to be a treatment for hepatitis C viral infections.
    Type: Application
    Filed: December 22, 2003
    Publication date: October 21, 2004
    Inventors: Benedikt Sas, Johan Van Hemel, Jan Vandenkerckhove, Eric Peys, Johan Van der Eycken, Bart Ruttens, Jan Balzarini, Eric De Clercq, Johan Neyts
  • Publication number: 20040180838
    Abstract: The use of bicyclic carbohydrates for the treatment of parasite infections is described. Different bicyclic carbohydrates have been tested in vitro against a number of protozoa. These compounds also have been screened against viruses, tumors, bacteria and fungi. Compound A1, a thiophenyl-containing bicyclic carbohydrate possessed significant activity against Trypanosoma brucei rhodiense, a parasite that causes the lethal sleeping sickness. Compound A2 and Compound A3, bicyclic carbohydrates with halogen containing aryl groups, possessed significant activity against Leishmania donovani, a parasite that causes leishmaniasis. Bicyclic carbohydrates in general, and Compound A1, Compound A2 and Compound A3 more specifically, could be possible treatments for the sleeping sickness and leishmaniasis in the future.
    Type: Application
    Filed: January 7, 2004
    Publication date: September 16, 2004
    Inventors: Benedikt Sas, Johan Van hemel, Jan Vandenkerckhove, Eric Peys, Johan Van der Eycken, Bart Ruttens
  • Publication number: 20030158243
    Abstract: Novel carbohydrate-based compounds with an attached ring system that have antimicrobial or cytostatic activity. The compounds are administered to humans and animals for the treatment or amelioration of bacterial, fungal, viral or protozoal infections or tumors.
    Type: Application
    Filed: October 15, 2001
    Publication date: August 21, 2003
    Inventors: Benedikt Sas, Johan Van der Eycken, Johan Van hemel, Petra Blom, Jan Vandenkerckhove, Bart Ruttens